House Appropriators Call For CMS To Pay More For Domestic Generic Drugs And Biosimilars
Executive Summary
Committee report sets manufacturing reshoring agenda for CMS and other HHS agencies like BARDA and ASPR that includes piloting new payment and reimbursement policies, strengthening domestic API production capabilities, and developing more flexible pharmaceutical manufacturing technologies that could add surge capacity.
You may also be interested in...
Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage
Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.
US FDA's Cavazzoni Criticizes Plant Shutdown That Triggered Serious Cisplatin Shortage
Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.